Launched in August, HTG’s Transcriptome Panel is designed to measure approximately 20,000 mRNA targets using EdgeSeq technology.
“I believe the ability to capture [approximately] 20,000 genes from a single tissue section with the HTG Transcriptome Panel will be a game-changer,” said Amir Horowitz, PhD, assistant professor of oncological sciences at Icahn Mount Sinai.
Through the collaboration, HTG will provide in-kind laboratory services in connection with three separate clinical study cohorts focused on bladder cancer from Icahn Mount Sinai.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.